Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share (EPS) of $3.98, up 30.8% [4][22] - In Q4 2025, revenue reached $826.4 million, a 25.7% increase compared to Q4 2024, with non-GAAP EPS of $1.28, growing 52.1% year-over-year [5][23] - The base business revenue for Q4 was $726.7 million, reflecting a 10.6% growth compared to the same quarter last year [5][25] - Adjusted EBITDA margin for Q4 was 35.7%, while the full year margin was 33.4% [6][24] Business Line Performance - The U.S. spine business grew by 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [6][27] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][26] - The trauma business experienced approximately 27% growth in Q4, supported by the legacy trauma line and precise limb lengthening products [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, reflecting a 19% increase [26][27] - The international spine business faced supply chain challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [28][80] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base [14] - Globus Medical is focused on expanding its core spine business while also growing adjacent markets through innovation and product development [18][19] - The company views competition in the enabling technology space as evolving but believes its ExcelsiusGPS system remains a strong offering [12][69] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and a robust sales force as key drivers [68] - The company anticipates continued margin expansion and has set a long-term goal for mid-seventies adjusted gross profit percentage [30][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates [80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a remaining authorization of $390 million under its share repurchase program [37][38] - Research and development expenses for Q4 were $36.2 million, or 4.4% of sales, reflecting a decrease from the prior year [30][32] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [47][48] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [54] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [59][60] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [68][69] Question: What are the headwinds in the international market? - Management highlighted that the international business can grow 12%-15% long-term, with a focus on deepening existing markets rather than expanding into new ones [80]